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Abstract  
AIM: To study the relation between adiponectin level with glycemic control and complication of 
diabetes.  
PATIENTS AND METHODS: The study included 40 female adolescent type 1 diabetic patients and 
40 healthy volunteers of the same age and sex. Blood sample was taken for assessment of 
glycosylated hemoglobin, lipid profile and adiponectine. Urine sample was taken for assessment of 
albumin/ creatinine ratio. 
RESULTS: Diabetic patients had a significantly higher diastolic blood pressure, triglyceride, total 
cholesterol, LDL and adiponectin than controls. Patients with diabetes complication had a 
significant lower BMI and HDL. On the other hand, they had higher disease duration, total 
cholesterol, HbA1, albumin/creatinine ratio and adiponectin. Patients with microalbuminuria had a 
lower BMI, higher disease duration, diastolic blood pressure and adiponectin. Patients with diabetic 
retinopathy had higher disease duration, insulin dose, HbA1, microalbuminuria and adiponectin. 
Adiponectin in diabetic patients had a significant negative correlation with BMI and positive 
correlation with systolic blood pressure and microlabuminuria.  
CONCLUSION: Serum adiponectin level is high in adolescent type 1 diabetic girls. It can be used 
as a predictor of diabetes complications rather than a sensitive biochemical marker for glycemic 
control. 
 
 
 
 
 
 
Introduction 
 
Adiponectin is a member of a group of 
adipose secreted proteins, sometimes described as 
adipocytokines. Adiponectin is a plasma protein that 
has been discovered few years ago. It is produced 
exclusively and abundantly in adipose tissue and 
circulates at relatively high concentration [1]. 
Adiponectin has great metabolic effects including 
enhancement of insulin sensitivity, reduction of 
hepatic glucose production and decreasing 
gluconeogenesis [2]. In addition, plasma adiponectin 
levels were found to be negatively correlated with 
body mass index (BMI) and fat content suggesting 
that fat mass may exert a negative feedback on 
adiponectin production [3].  
 
The circulating concentrations of 
adipocytokines are abnormal in type 1 diabetic 
children. The direction of change differs according to 
cytokine, pubertal development; in addition to insulin 
therapy and glycemic control [4]. The relationship 
between serum adiponectin concentration and 
pancreatic B cell function is a significant negative 
modulator for circulating adiponectin in diabetic 
patients and support the presence of adipoinsular axis 
[5]. 
We are aiming to determine the influence of 
adolescent girls with type 1 DM on circulating levels of 
adiponectin and to study the relation between 
adiponectin level with glycemic control and 
complication of diabetes. 
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Patients and Methods 
 
It is a cross-sectional observational study 
done after obtaining approval from the ethical 
committee of the National Research Centre, Cairo, 
Egypt. It conforms to the provisions of the Declaration 
of Helsinki (as revised in Edinburgh 2000). Written 
informed consent was obtained from all patients, their 
parents and controls after full discussion about the 
aim of the study.  
The study included 40 female adolescents 
with type 1 diabetes mellitus attending the Pediatric 
Endocrinology Out-patient Clinic, National Research 
Center, Cairo, Egypt. Patients with type 1 diabetes 
were defined according to the criteria of American 
Diabetes Association [6]. Another group of 40 age 
matched healthy female adolescents with no obvious 
medical disorders and not receiving any medication 
were enrolled as a control group. 
Inclusion criteria are type 1 diabetic females 
on insulin therapy with age between 9-18 years. 
Exclusion criteria are adolescent girls with other 
chronic diseases. 
 
Methods 
All included cases were subjected to full 
medical history taking. 
Assessment of anthropometric measures 
including weight in kilograms (kg), height in 
centimeters (cm) and body mass index (BMI) was 
measured as kg/m
2
 and plotted on age and sex 
matched Egyptian standard BMI percentiles [7].  
Measurement of blood pressure (mmHg) was 
obtained after a 5-minute rest in the seated position 
using mercury sphygmomanometer. Blood pressure 
values were considered as hypertension if mean 
values (systole/diastol) were greater than 90
th 
percentile for age and sex. Blood pressure 
measurement was repeated twice for the validity of 
the reading [8]. 
Clinical examination include: chest, cardiac, 
abdomen and neurological examination. Neurological 
examination: Clinical neuropathy was diagnosed in 
patients with two or more of the following four 
measures: the presence of one or more symptoms of 
diabetic neuropathy (tingling, numbness, impaired or 
lost sensation), the absence of two or more reflexes of 
the ankle or knee tendons, a vibration perception 
threshold was abnormal for the patient's age, and 
abnormal autonomic function (postural hypotension 
with a fall in systolic blood pressure of ~20 mmHg) [9]. 
Reviewing the records of routine annual 
fundus was examined by indirect ophthalmoscope 
through dilated pupils for assessment of diabetic 
retinopathy. Patient was defined as having diabetic 
retinopathy if the following diabetic retinal changes 
were present; micro-aneurysms, capillary leakage, 
micro-infarcts, macular edema, traction detachment of 
the macula or vitrous hemorrhage [10]. 
All patients and controls underwent the 
following tests: For cholesterol measurements, 
venous blood was sampled after a 12-h fast. Serum 
total cholesterol was determined by a commercial kit 
(Boehringer-Mannheim, Germany) [11]. High-density 
lipoprotein (HDL) cholesterol was separated from the 
serum by precipitation of the other lipoproteins with a 
heparin/manganese procedure [12]. Low-density 
lipoprotein (LDL) cholesterol was calculated using the 
Friedewald equation. The concentration of 
triglycerides(Tg) was measured in a TechnoCon 
AutoAnalyzer II (TechnoCon Instruments, Tarrytown, 
NY, USA).  
Assessment of glycosylated hemoglobin % 
(HbA1 %) ; peripheral blood samples were collected 
on ethelene diamine tetra-acetic acid (EDTA) (1.2 
ng/ml) for assay of HbA1 % using D-10 (BioRad, 
France) and reviewing two previous readings to 
calculate the mean value of HbA1 % in the last year 
prior to the study [13]. Reviewing the records of 
urinary albumin execretion in an early morning fasting 
urine sample was determined as urinary albumin-to-
creatinine ratio (UACR) by immune-turbidimetric 
method (Cobas Integra SOO; Roche Diagnostics, 
Mannheim, Germany). Patients were diagnosed as 
having microalbuminuria or macro-albuminuria when 
UACR in at least 2 out of 3 consecutive urine 
samples, 2 months apart was 30-299 mg/g creatinine 
or ≥ 300 mg/g creatinine, respectively [14]. 
Adiponectin measurement by ELISA technique was 
also done [15]. 
Table 1:  Comparison between demographic and laboratory 
data of patients and control group  
 Patients group Control group   
 (n= 40) (n= 40) Independent t-test 
 Mean SD Mean SD t p-value 
Age (yrs) 12.44 2.48 12.39 2.14 0.096 0.922 
Weight(Kg) 46.85 12.35 44.04 12.77 -1.001 0.320 
Height (cm) 146.78 15.66 142.41 14.16 -1.307 0.195 
BMI (kg/m
2
) 21.60 3.98 21.33 3.71 -0.313 0.755 
SBP (mmHg) 114.25 7.47 111.75 7.12 -1.532 0.130 
DBP (mmHg) 74.25 5.94 71.75 6.36 -1.816 0.043 
Triglycerides (mg/dl) 97.38 18.25 86.65 13.52 -2.987 0.004 
Total cholesterol (mg/dl) 148.35 30.43 125.28 21.48 -3.918 0.0001 
LDL cholesterol (mg/dl) 100.38 22.21 82.98 16.42 -3.983 0.0001 
HDL cholesterol (mg/dl) 47.48 14.69 42.92 13.06 -1.464 0.147 
CRP  (µg/mL) 2.25 1.08 2.20 0.88 -0.227 0.821 
Adiponectin (µg/mL) 14.63 2.20 8.11 1.50 -15.468 0.0001 
BMI : Body mass index, SBP: systolic blood pressure, DBP: Diastolic blood pressure, LDL: 
low density lipoprotein. HDL: high density lipoprotein, CRP: C-reactive protein 
 
 
Statistical Methods 
Statistical analysis was conducted using 
Statistical Package for Social Science (SPSS) 
program version 15.0 (Chicago, Illinois, USA). t -test 
for independent variables was done. Pearson 
correlation was also done.  
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Results 
 
The study included 40 type 1 diabetic 
patients, their mean age was 14.4 ± 2.5, mean 
duration of diabetes was 10.1 ± 2.8 and mean insulin 
dose was 1.4 ± 0.5 U/kg. Diabetic patients had a 
significantly higher diastolic blood pressure, 
triglyceride, total cholesterol, LDL and adiponectin 
than controls (Table 1). Patients with diabetic 
complication had a significant lower BMI and HDL. On 
the other hand, they had higher disease duration, total 
cholesterol, HbA1, albumin/creatinine ratio and 
adiponectin (Table 2).  
Table 2: Comparison between demographic and laboratory 
data of our patients regarding  diabetic complications  
 Patients without Patients with Independent 
 
diabetic 
complications  
N = 29 
 
diabetic 
complications 
N =11 
t-test 
 Mean SD Mean SD t P-value 
Age (yrs) 14.09 2.71 14.86 2.17 -0.977 0.335 
Weight(Kg) 49.91 14.10 43.11 8.80 1.779 0.041 
Height (cm) 145.14 17.48 148.78 l3.32 -0.727 0.472 
BMI (kg/m
2
) 23.33 3.70 19.47 3.28 3.450 0.001 
SBP (mmHg) 115.00 7.40 113.33 7.67 0.697 0.490 
DBP (mmHg) 75.00 5.98 73.33 5.94 0.880 0.384 
Disease duration (yrs) 8.93 2.48 11.53 2.65 -3.195 0.003 
Insulin dose (U/Kg/day) 1.26 0.41 1.58 0.62 -1.998 0.043 
Triglycerides (mg/dl) 96.77 17.36 98.11 19.77 -0.228 0.821 
Total cholesterol (mg/dl) 137.64 29.34 157.00 28.51 2.241 0.031 
LDL cholesterol (mg/dl) 105.45 23.63 94.17 19.19 1.633 0.111 
HDL cholesterol (mg/dl) 52.18 14.57 41.72 13.00 2.369 0.023 
CRP  (µg/mL) 2.09 0.87 2.47 1.33 -1.078 0.288 
HbA1 (%) 9.42 1.55 12.19 2.79 -3.978 0.0001 
Albumin/ creatinine ratio 
(mg/ gm creatinine) 
18.68 5.81 130.72 104.71 -5.024 0.0001 
Adiponectin (µg/mL) 13.49 1.91 16.02 1.70 -4.369 0.0001 
BMI : Body mass index, SBP: systolic blood pressure, DBP: Diastolic blood pressure, LDL: 
low density lipoprotein. HDL: high density lipoprotein, CRP: C-reactive protein 
 
Patients with microalbuminuria had a lower 
BMI, higher disease duration, diastolic blood pressure 
and adiponectin (Table 3).  
Table 3: Comparison between demographic and laboratory 
data of our patients regarding  microalbuminuria 
 
Patients with normo 
albuminoria 
Patients with 
microalbuminuria 
Independent t-
test 
N=29 N=11   
Mean SD Mean SD t 
p-
value 
Age (years) 14.41 2.56 14.50 2.38 -0.097 0.923 
Weight (Kg) 49.12 13.11 40.86 7.72 1.955 0.058 
Height (cm) 146.48 17.09 147.55 11.75 -0.189 0.851 
BMI (kg/m
2
) 22.72 4.00 18.64 1.94 3.224 0.003 
SBP (mmHg) 111.17 6.88 115.82 8.74 1.278 0.209 
DBP (mmHg) 75.17 5.75 81.82 6.03 1.627 0.012 
Disease duration (yrs) 9.21 2.69 12.45 1.68 -3.720 0.001  
Insulin dose (U/Kg/day) 1.33 0.43 1.59 0.73 1.430 0.161 
Triglycerides (mg/dl) 98.07 18.97 95.55 16.93 0.386 0.701 
Total cholesterol (mg/dl) 150.03 29.38 143.91 34.12 0.563 0.576 
LDL cholesterol (mg/dl) 101.55 22.32 97.27 22.70 0.539 0.593 
HDL cholesterol (mg/dl) 47.79 15.03 46.64 14.44 0.220 0.827 
CRP  (µg/mL) 2.24 1.06 2.27 1.19 -0.081 0.936 
HbA1 (%) 10.59 2.54 10.87 2.79 -0.303 0.764 
Albumin/ creatinine 
ratio (mg/ gm 
creatinine) 
19.00 6.23 201.18 67.52 
-
14.679 
0.0001 
Adiponectin (µg/mL) 13.85 2.05 16.69 0.78 -4.444 0.0001 
BMI : Body mass index, SBP: systolic blood pressure, DBP: Diastolic blood pressure, LDL: 
low density lipoprotein. HDL: high density lipoprotein, CRP: C-reactive protein. 
 
Patients with diabetic retinopathy had higher 
disease duration, insulin dose, HbA1, 
microalbuminuria and adiponectin (Table 4).  
Table 4:  Comparison between demographic and laboratory 
data of our patients regarding diabetic retinopathy 
 
Patients 
without 
Patients with   
 retinopathy retinopathy Independent 
 (n=29) (n=11) t-test 
 Mean SD Mean SD t p-value 
Age (years) 14.10 2.69 15.32 1.59 -1.401 0.169 
Weight (Kg) 48.26 13.38 43.14 8.52 1.177 0.247 
Height (cm) 146.59 16.83 147.27 12.76 -0.122 0.903 
BMI (kg/m
2
) 22.20 3.94 19.99 3.79 1.600 0.118 
SBP (mmHg) 113.79 8.20 115.45 5.22 -0.623 0.537 
DBP (mmHg) 74.48 6.32 73.64 5.05 0.398 0.693 
Disease duration (yrs) 9.62 2.69 11.36 2.98 -1.779 0.043 
Insulin dose (U/Kg/day) 1.23 0.39 1.86 0.59 3.900 0.0001 
Triglycerides (mg/dl) 99.28 17.89 92.36 19.10 1.072 0.291 
Total cholesterol (mg/dl) 152.28 31.70 138.00 25.21 1.338 0.189 
LDL cholesterol (mg/dl) 101.79 23.32 96.64 19.51 0.651 0.519 
HDL cholesterol (mg/dl) 50.48 15.11 39.55 10.36 2.204 0.034 
CRP  (µg/mL) 1.93 0.84 3.09 1.22 -3.424 0.072 
HbA1 (%) 9.57 1.99 13.57 1.43 -6.093 0.0001 
Albumin/creatinine ratio (mg/gm 
creatinine) 
49.69 77.97 120.27 100.70 -2.358 0.024 
Adiponectin (µg/mL) 14.01 2.20 16.26 1.16 -3.204 0.003 
 
BMI : Body mass index, SBP: systolic blood pressure, DBP: Diastolic blood pressure, LDL: 
low density lipoprotein. HDL: high density lipoprotein, CRP: C-reactive protein 
 
Adiponectin in diabetic patients had a 
significant negative correlation with BMI and positive 
correlation with systolic blood pressure and 
microlabuminuria (Table 5). Six patients (15%) had 
symptoms and signs of diabetic neuropathy, 11 
patients (27.5 %) had diabetic retinopathy by indirect 
ophthalmoscope and 11 patients (27.5%) had 
microalbuminuria. 
Table 5:  Correlation between serum adiponectin and different 
parameters in patients group 
 Adiponectin (g/ml) 
Variables   
 r p-value 
Age (years) 0.070 0.666 
Weight (Kg) -0.486 0.001 
Height (cm) 0.072 0.658 
BMI (kg/m
2
) -0.767 0.0001 
SBP (mmHg) 0.692 0.0001 
DBP (mmHg) 0.100 0.538 
Disease duration (yrs) -0.l27 0.434 
Insulin dose (U/Kg/day) -0.056 0.730 
Triglycerides (mg/dl) -0.066 0.685 
Total cholesterol (mg/dl) -0.261 0.104 
LDL cholesterol (mg/dl) -0.175 0.279 
HDL cholesterol (mg/dl) -0.262 0.102 
CRP  (µg/mL) -0.104 0.522 
HbA1 (%) 0.224 0.165 
Albumin/ creatinine ratio (mg/gm creatinine) 0.611 0.0001 
 
BMI: body mass mdex- SBP: systolic blood pressure-DBP: diastolic blood pressure-LDL: 
low density Iipoprotein- HDL: high density Iipoprotein-CRP: C reactive protein-  
 
 
Discussion 
 
In the present study, diastolic blood pressure, 
cholesterol, triglyceride, LDL-c and adiponectin were 
significantly higher in diabetic patients than controls. 
On the other hand CRP as a marker of infection 
revealed no significant difference in diabetics and 
controls. Similar other studies have shown that, the 
absolute concentrations of total adiponectin and all 
subforms were higher in type 1 DM patients than 
healthy controls [4]. This increase in concentration of 
total adiponectin was primarily caused by a major 
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increase of the high molecular weight (HMW) sub-
form as reported by Barnes et al., [16] and Galler et 
al., [17]. Contrary to the present study, others reported 
no significant difference in serum adiponectin levels 
between type 1 diabetic patients and healthy controls 
[18]. The causes of the differences among the 
different studies are not clear, but they may be 
attributed to differences in ages at diagnosis, ethnic 
backgrounds and genetic factors such as different 
HLA values and autoantibody frequency [19]. 
Several studies showed that, circulating 
concentrations of adiponectin are higher in type 1 
diabetic patients than in controls, while in type 2 
diabetic patients, adiponectin levels are lower than 
controls [18, 20]. It has been proposed that this may 
be related to insulin's down regulation on adiponectin 
secretion. Therefore, in type 1 diabetic patients, 
insulin deficiency may be associated with higher 
adiponectin levels [21]. Adiponectin has been 
demonstrated to have an impact on glucose 
homeostasis. In addition to its insulin-sensitizing 
effects, adiponectin may alter glucose metabolism 
through stimulation of pancreatic insulin secretion in 
vitro, suggesting that pancreatic beta cell function is 
one of a significant negative modulator for the 
circulating adiponectin level in diabetic patients and 
support the presence of adipoinsular axis [5]. 
In the current study, adiponectin had a 
significant negative correlation with body weight and 
body mass index (BMI). In the contrary a longitudinal 
study from Germany showed that children and 
adolescents with type 1 diabetes have BMI-dependent 
elevated serum adiponectin compared with healthy 
children [17]. Other study demonstrated that serum 
adiponectin was inversely correlated with skin fold 
thickness rather that BMI and it has been suggested 
that skin folds seemed more closely associated with 
adiponectin than BMI [21].  
In the current study, there was no significant 
correlation between any of lipid parameters and 
serum adiponectin level. A study done by Patel et al., 
[22] showed no correlation between adiponectin level 
and carotid intimal medial thickness (CIMT). However, 
another study showed that, adiponectin is considered 
to be inversely related to obesity and dyslipidemia, 
and low levels of adiponectin have been linked to 
cardiovascular disease. The link between adiponectin 
and the metabolic syndrome (or abdominal obesity 
and low HDL cholesterol) is concealed by the overall 
increase of adiponectin due to diabetes complications 
[23]. 
In the present study, no significant correlation 
was found between serum adiponectin and HbA1. 
Similar finding was demonstrated by a recent study 
[19]. On the contrary, another study showed that, 
serum adiponectin level in patients with poor glycemic 
control is higher than in patients with good glycemic 
control and has direct association with HbA1 % in type 
1 diabetics, so it can be used as a good marker for 
metabolic state among these patients [8]. Also other 
studies found such correlation with the HbA1% [4, 24]. 
A study done by Wang et al., [25] put an explanation 
for the effect of glycemic control on serum adiponectin 
levels. They found that the collagenous domain of the 
adiponectin molecule has four conserved lysines. In 
diabetic patients, glycosylation of these molecules 
with constant hyperglycemia could lead to a modified 
adiponectin molecule and an altered adiponectin 
function. Consequently, this could lead to diminished 
negative feedback, and thus to increased adiponectin 
concentrations in diabetics. 
In the present study, 45 % of our diabetic 
patients had one or more of diabetic complications 
(diabetic neuropathy, retinopathy and or 
nephropathy). Patients with diabetic complications 
had a significant lower body weight, BMI and serum 
HDL. On the other hand, they had a significant higher 
insulin dose, disease duration, total cholesterol, HbA1, 
urinary albumin/creatinine ratio and serum 
adiponectin. This is in agreement with Morales et al., 
[18], Galler et al., [17] and Lindstrom et al., [26] who 
found the same results, in accordance with our results 
they reported that, serum adiponectin level was 
significantly higher in type 1 diabetic patients with 
longer disease duration (> 10 years) and they 
attributed high adiponectin level to renal function 
deterioration related to diabetes duration. Similar 
another Egyptian study evaluated adiponectin levels 
in children and adolescents with type 1 diabetes and 
relationship to long term complications. This study 
revealed that serum adiponectin was significantly 
elevated; urinary albumin/creatinine ratio and mean 
HbA1 were significantly higher in complicated 
patients. Moreover, patients with nephropathy showed 
higher values of adiponectin. So, elevated adiponectin 
level in adolescent girls with type 1 diabetes indicated 
development of complications, especially nephropathy 
[24]. Furthermore, Hadjadj et al., [27] reported that 
elevated adiponectin observed in diabetics with 
microvascular and macrovascular diseases; 
nephropathy, retinopathy, neuropathy and in a single 
patient with cardiomyopathy; that revealed an altered 
regulation of this adipocytokine in patients with 
complications associated with type 1 diabetes. 
Patients with microalbuminuria had a 
significant longer disease duration and higher serum 
adiponectin level compared to normoalbuminuric 
patients. This in accordance with Hovind et al., [28] 
who mentioned that the development of 
microalbuminuria in patients with type 1 diabetes 
usually begins 5 to 15 years after the onset of 
diabetes and then increases over time. A small 
proportion of patients develop microalbuminuria within 
less than five years of disease onset Moreover, in a 
systematic review of nine longitudinal studies 
examining microalbuminuria in 7938 patients with 
Type I DM, the overall prevalence of microalbuminuria 
was (28 %) at a mean duration of diabetes of 15 
years. In another report, the prevalence of 
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microalbuminuria reached (52%) at 30 years [29]. 
Adiponectin probably increases as a compensatory 
response in these patients with microvascular 
complications and acts as a physiological response to 
restrict endothelial damage. However, later 
adiopnectin clearance decreased and the kidney may 
develop secondary resistance to adiponectin with 
further increase in its serum level [30]. 
In the current study, 11 patients (27.5%) had 
diabetic retinopathy. Patients with diabetic retinopathy 
had a significant higher insulin dose, disease duration, 
HbA1, urinary albumin/creatinine ratio and serum 
adiponectin. Chronic hyperglycemia is thought to be 
the primary cause of diabetic retinopathy, this 
hypothesis was supported by diabetes Control and 
Complications Trial (DCCT), which found that 
intensive insulin therapy, achieving a mean HbA1 % 
of 7.9 %, reduce the incidence of retinopathy by as 
much as 76% compared with conventional therapy. 
The reduction was directly related to the degree of 
glycemic control as estimated by HbA1 % [31]. 
Habeeb et al, [24] and Zieta et al [32] reported 
that adiponectin was elevated in patients with diabetic 
retinopathy. On the other hand, Yilmaz et al., [33] 
showed that adiponectin concentrations were lower in 
patients with diabetic retinopathy. On the other hand, 
Horta et al., [34] suggested that plasma levels of 
adiponectin did not differ between patients with and 
without diabetic retinopathy.  
Nagaoka et al., [35] reported that adiponectin 
induced vasodilatation of the retinal arterioles through 
activation of adipo R1 and/or adipo R2 in the retinal 
endothelial cells, and adiponectin may be involved in 
retinal blood flow (REF) regulation. Because the RBF 
is impaired in early-stage in patients with diabetic 
retinopathy, therapeutic interventions that enhance 
the actions of adiponectin may lead to a novel 
potential treatment. It remains to be clarified whether 
increased concentrations of adiponectin are 
pathogenically related to the development of diabetic 
retinopathy or merely a beneficial counter-regulatory 
response. A recent meta-analysis on association 
between adiponectin concentration and diabetic 
retinopathy found a significant association and 
revealed high heterogeneity may be because of the 
plasma adiponectin levels are influenced by various 
factors such as; degree of obesity, age, blood lipid, 
gender, glucose level, kidney function, 
pharmacological therapy with thiazolidinediones [36]. 
Finally, serum adiponectin was found to have 
highly statistically significant negative correlations with 
weight and BMI in female adolescent with type 1 
diabetes. This is in agreement with Kishida et al. [37] 
who found such negative correlation. 
We conclude that serum adiponectin level is 
high in adolescent type 1 diabetic girls. It can be used 
as a predictor of diabetic complications rather than a 
sensitive biochemical marker for glycemic control. 
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